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ARTICLE

OPEN

Rabies virus-based COVID-19 vaccine CORAVAX™ induces
high levels of neutralizing antibodies against SARS-CoV-2
Drishya Kurup

1,3

, Christoph Wirblich1,3, Holly Ramage1,2 and Matthias J. Schnell

1,2 ✉

The recently emerged coronavirus SARS-CoV-2, the causative agent of COVID-19, is rapidly spreading in the world. The
exponentially expanding threat of SARS-CoV-2 to global health highlights the urgent need for a vaccine. Herein we show the rapid
development of a novel, highly efﬁcient, and safe COVID-19 vaccine using a rabies virus-based vector that has proven to be an
efﬁcient vaccine against several emerging infectious diseases. This study reports that both a live and an inactivated rabies virus
containing the SARS-CoV-2 spike S1 protein induces potent virus-neutralizing antibodies at much higher levels than seen in the sera
of convalescent patients. In summary, the results provided here warrant further development of this safe and established vaccine
platform against COVID-19.
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INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a
zoonotic pathogen belonging to the Betacoronavirus family,
emerged in December 2019 in Wuhan, China. SARS-CoV-2 rapidly
engulfed the world in a coronavirus disease (COVID-19) pandemic
infecting more than 22.4 million people and resulting in at least
789,455 deaths (Johns Hopkins University, accessed August 20,
2020)1. Among the seven coronaviruses that cause respiratory
disease in humans, four cause only mild infection (229E, NL63,
OC43, and HKU1), and three are highly pathogenic (SARS-CoV,
MERS, and SARS-CoV-2). SARS-CoV-2 most likely originated in bats
and was transmitted to humans via an intermediary animal host,
as has been shown for the other highly pathogenic human
Coronaviruses MERS and SARS-CoV2. The molecular determinants
behind the high transmissibility and pathogenicity of SARS-CoV-2
are still hypothetical, but the acquisition of a furin cleavage site in
the spike protein as well as mutations in the receptor binding
domain which allow the spike protein to bind to human
angiotensin-converting enzyme (ACE2) appear to be critical/
important factors3–5. The presence of these and perhaps other
molecular signatures have made SARS-CoV-2 the most easily
transmissible of the three pathogenic Coronaviruses. Unlike SARS,
SARS-CoV-2 will probably not be eliminated or even contained
until an effective vaccine becomes available.
ACE2 receptors have been found to mediate cellular entry of
SARS-CoV-2 as well as other coronaviruses, including NL63 and
SARS-CoV, with which SARS-CoV-2 shares a 76% amino acid
identity5. Cells expressing ACE2 are susceptible to the SARS-CoV-2
Spike (S) glycoproteins, which project from the surface of the
SARS-CoV-2 virion membrane and act as ligands2. In humans,
neutralizing antibodies and/or T-cell immune responses are raised
against several SARS-CoV-2 proteins but mainly target the S
protein, suggesting that S protein-speciﬁc immune responses play
an important part in protection6. Therefore, most vaccine
approaches currently use the SARS-CoV S protein, or part of it,
as the vaccine immunogen7.

More than 139 different vaccines against COVID-19 are currently
in preclinical development; of these, thirty are in clinical trials8,9.
These vaccines can be allocated to one of three different
platforms: synthetic vaccines based on DNA or RNA; virus-like
particles; or inactivated virions or viral vectors expressing part of
the SARS-CoV-2 genes10. While an effective vaccine candidate is
yet to be identiﬁed, the most promising candidates can be
expected to induce virus-neutralizing antibodies that have been
described as a hallmark for protection against coronaviruses11.
Here we present a rabies virus (RABV)-based vaccine that offers
a combination of features that could prove valuable for an
effective, globally distributed SARS-CoV-2 vaccine. Additionally, we
have demonstrated protection against another coronavirus, MERSCoV, in challenge studies in mice utilizing the same RABV vector
platform12. Our previous work has proven that both live and
chemically inactivated RABV vaccines are safe for animals13,14.
Furthermore, since the RABV vaccine often provides life-long
immunity, long-term stability of the SARS-CoV-2 immune
responses will be assessed in future studies.

RESULTS
We introduced the SARS-CoV-2 S1 protein into the attenuated
RABV vector based on our previous work with MERS-CoV (Fig. 1a).
The RABV vaccine vector that we utilized derives from the
attenuated RABV SAD-B19 vaccine strain15. Several modiﬁcations
were introduced into the parent strain to increase its safety and
maximize the expression of foreign genes. As previously shown,
the expression of foreign antigens between the RABV N and P
gene, as well as target gene codon optimization for human cells,
results in the highest expression level of the foreign antigen13.
Previous research with full-length MERS-CoV S also indicated that
the full-length S protein of coronaviruses reduces viral titers
dramatically, so we utilized the S1 subunit of the SARS-CoV-2 S.
More importantly, the S1 domain containing the receptor-binding
domain (RBD) is less conserved than the S2 fusion domain (64%
vs. 90% identity with SARS-CoV)16.
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Fig. 1 Characterization of the CORAVAX vaccine. a Schematic illustration of CORAVAX, the rabies virus-based SARS-CoV-2 vaccine construct
used in this study. A SARS-CoV-2 S1 RABV G chimeric protein cDNA was inserted between the N and P genes of the SAD-B19-derived RABV
virus vaccine vector BNSP333. b Immunoﬂuorescence staining of Vero cells at 48 h post-infection labeled for either the RABV G protein (green)
or the SARS-CoV-2 S1 protein (red).Scale bar represents 30 μm. c SDS-PAGE analysis of puriﬁed virions after sucrose gradient puriﬁcation.
Letters indicate the positions of the RABV L, G, N, P, and M and the chimeric S1-RABV-G proteins. d The panel shows western blotting of
puriﬁed CORAVAX or control RABV(BNSP333) particles probed with anti-SARS-CoV-2 S rabbit polyclonal antibody or a human monoclonal
4C12 antibody directed against RABV G. All blots derive from the same experiment and were processed in parallel. Full size gels and WB are
presented in the Supplemental material.
npj Vaccines (2020) 98
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Fig. 2 Conformational characterization of chimeric S1 in CORAVAX. Binding of a constant amount of a recombinant hACE2-Fc chimera and
b Anti-RBD mIgG2a antibody to a dilution series of CORAVAX, RBD-His tag protein and BNSP333.

To promote the incorporation of the S1 domain; we prepared a
fusion protein between SARS-CoV-2 S1 and RABV G. Toward this
approach the N-terminal 681 aa of SARS-CoV-2 S1 were fused to a
truncated RABV glycoprotein, which comprises 31 aa of the
ectodomain (ED) of RABV G and the complete cytoplasmic domain
(CD) and transmembrane domain of RABV G to allow chimeric
glycoprotein incorporation into RABV virions. The use of the
transmembrane domain, as well as the cytoplasmic domain, has
been shown previously to promote incorporation in RABV
particles12. The chimeric SARS-CoV-2 S1/RABV G protein utilized
the original SARS-CoV-2 ER translocation sequence (SS) and was
generated by PCR of codon-optimized cDNA fragments. This
construct was named CORAVAX™ (Fig. 1a). CORAVAX was
recovered from cDNA on BSR or VERO cells, and viral stocks were
prepared as described in the method section.
Next, we characterized the recombinant viruses. Vero cells were
infected at a multiplicity of infection (MOI) of 0.01 with CORAVAX
or empty RABV vector (BNSP333) or mock-infected. CORAVAXinfected cells stained for both RABV-G (green) and SARS-CoV-2
(red), while the empty RABV vector BSP333 stained only for RABVG and the mock-infected cells did not stain (Fig. 1b). Importantly,
both RABV G and SARS-CoV-2 S1 are expressed at similar regions
of the cell surface, indicating the likelihood of co-incorporation
into the virions, an essential requirement for the use of such
recombinant particles as an inactivated vaccine. To further analyze
the incorporation of the two glycoproteins, supernatants from
CORAVAX- or vector BNSP333- infected VERO cells were concentrated and puriﬁed over a 20% sucrose and separated by SDSPAGE. As shown in Fig. 1c, all ﬁve RABV proteins were detected for
both CORAVAX and BNSP333. For CORAVAX, however, an
additional protein band migrating at the expected size of
150 kDa for S1 was detected. Utilizing a SARS-CoV-2 speciﬁc
antibody, we conﬁrmed the presence of the chimeric SARS-CoV-2
-RABV G fusion protein as well as RABV-G by western blotting
(Fig. 1d). In CORAVAX, we also observed differentially glycosylated
RABV-G, which may be attributed to the addition of the S1 domain
(Fig. 1d).
While the biochemical characterization of CORAVAX conﬁrmed
the successful incorporation of chimeric S1 into rabies virus
particles, the antigen’s conformation was not addressed. To assess
the correct conﬁrmation of the chimeric S1 incorporated into
CORAVAX, we ﬁrst analyzed the binding of the recombinant
human ACE-2 receptor-Fc chimera (human IgG) protein (Fig. 2a)
and a SARS-COV-2 receptor binding domain (RBD) directed mouse
monoclonal antibody (Fig. 2b). As shown in Fig. 2a, b, both the
RBD antibody and the recombinant human ACE-2 receptor-Fc
chimera protein bind to CORAVAX in a dose-dependent manner,
indicating the proper folding of the S1 domain. The positive
control RBD-His tag bound to the RBD mouse monoclonal and the
Published in partnership with the Sealy Center for Vaccine Development

hACE-2 receptor-Fc chimera protein while the negative control
BNSP333 showed no signal.
To study the immunogenicity of the CORAVAX vaccine, we
immunized groups of ﬁve BALB/c mice with live 107 foci forming
units (ffu) CORAVAX at day 0; 10 μg inactivated CORAVAX or
10 μg inactivated CORAVAX virions adjuvanted with MPLAAddaVax at day 0 and 21 (Fig. 3a). Serum was collected on days
0,14, 21, 28, and 56 after the ﬁrst immunization and analyzed for
the presence of IgG against SARS-CoV-2 S by SARS-CoV S1speciﬁc ELISA assay, as described in the methods section. All
three vaccine approaches induced seroconversion and antibodies directed against the SARS-CoV-2 S (Fig. 3b). The detected
humoral immune responses increased about ten-fold after the
boost at day 21 for the inactivated vaccines. Interestingly, even
the immune responses induced by the single inoculations with
the live RABV slightly increased over time, indicating the
medium-term immunostimulatory nature of the vector. To
conﬁrm the ELISA results observed with the recombinant
SARS-CoV-2 S1, we performed ELISA’s utilizing the SARS-CoV-2
RBD as a target. Of note, antibodies detected against RBD have
been indicated to predict virus neutralization antibodies (VNA)
against SARS-CoV-217–20. The results shown in Fig. 3c suggest
that the immune responses were very similar to the S1 ELISA
with the highest responses detected for animals immunized
twice with adjuvanted CORAVAX and the lowest detected for the
live viral vector.
Th1 responses are beneﬁcial for protection against viral diseases
and such responses have been shown to prevent pathology in the
SARS-CoV S based vaccine model, we examined the induction of
IgG isotypes after immunization at day 56. The live viral CORAVAX
vaccine induced a balanced Th1/Th2 response while the killed
vaccine with or without the adjuvant induced a more pronounced
Th1-biased response (Fig. 3d).
Having shown that our vaccine CORAVAX is immunogenic, we
further analyzed the potency of the induced antibodies. Development of virus neutralizing antibodies (VNA) have shown some
correlation of protection against SARS COV-211,21,22. As shown in
Table 1, panel A, the sera (each group was pooled) from the live
and inactivated vaccinated animals induce a high level of SARSCoV-2 neutralizing antibodies, which aligns well with the SARSCoV-2 S1 antibodies detected by ELISA, e.g., higher antibody titers
detected in the S1-speciﬁc ELISA resulted in higher VNA. Both the
adjuvanted and unadjuvanted vaccines resulted in high SARSCoV-2 VNA, blocking 100% of the infection at a dilution of
1:600–1:1200, which is 20-fold more elevated than two different
human convalescence sera we included as controls in the VNA
assay. Sera collected from a patient during acute infection showed
SARS-CoV-2 VNA was higher but still below the level in the sera
from vaccinated mice. The presence of VNA is undoubtedly the
npj Vaccines (2020) 98
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a
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CORAVAX™ Live
CORAVAX™ inact.
CORAVAX™ inact. + MPLA-AddaVax (Adjuvant)

b

c

d

Fig. 3 Analysis of the immune response to CORAVAX in mice. Balb/C mice were immunized once with live CORAVAX or twice (days 0 and
21) with 10 μg chemically inactivated particles of CORAVAX with or without adjuvant. Serum was collected from each mouse at days 14, 21, 28,
42, and 56 for analysis by a SARS-CoV-2 S-speciﬁc ELISA. a Immunization schedule: live CORAVAX used once on day 0; the inactivated vaccines
were dosed on days 0 and 28 (ﬁgure created with BioRender.com). b SARS CoV-2 S1 IgG responses represented as EC50 titers c SARS CoV-2
RBD IgG responses on day 56 sera d SARS CoV-2 S1 IgG2/1 isotype ratio. Two animals in the inactivated CORAVAX group did not make
detectable IgG1 antibodies.
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Table 1.

Virus neutralizing antibodies against SARS-CoV-2 and RABV.

A
Serum – mice pooled

Day 0 anti-SARS- Day 56 antiCoV-2 VNA
SARS-CoV-2 VNA

CORAVAX live

0

1:250

CORAVAX inact.
CORAVAX inact. + MPLAAddaVax

0
0

1:600
1:1200

BNSP333 (RABV Vector)
Serum – human

N/A
anti-SARS-CoV2 VNA
1:35

0

Convalescent serum human 1
Convalescent serum human 2

1:27.5

Acute infection human serum

1:240

Pre COVID-19 RABV vaccinated
human serum

0

B
Serum – mice pooled

Day 0 antiRABV VNA

Day 56 antiRABV VNA

CORAVAX live

0 IU

6.7 IU

CORAVAX inact.

0 IU

20 IU

CORAVAX inact. + MPLAAddaVax

0 IU

140 IU

BNSP333 (RABV Vector)

N/A

46.7 IU

Serum – human

anti-RABV VNA

Convalescent serum human 1

0 IU

Convalescent serum human 2

0 IU

Acute infection human serum 0 IU
Pre COVID-19 RABV vaccinated 50 IU
human serum
Sera from CORAVAX vaccinated mice neutralize SARS-CoV-2 and RABV.
Neutralization assays analyzed pooled sera from immunized mice against
SARS-CoV-2 on Vero cells. The dilution at which SARS-CoV-2 infection was
no longer detected by immunostaining against SARS-CoV-2 is shown as an
average for two independent experiments (Table 1, panel A). Rabies
neutralizing titers were assesed by RFFIT assay and represented as
international units (IU) (Table 1, panel B).

ﬁrst step to identify a potentially useful vaccine. However, reports
that pathology can occur even in the presence of VNA will need to
be addressed in an appropriate animal system23,24.
We have previously demonstrated that the RABV-based Ebola
virus (EBOV) vaccine immune responses observed in mice
translate well to nonhuman primates (NHPs), at least against
RABV G13,25. Because the expression of SARS-CoV-2 reduced
expression of RABV G on the cell surface and also reduced the
incorporation of RABV G into the RABV virus (Fig. 1d), we
performed VNA assays against RABV. The results shown in Table 1,
panel B indicate that all animals immunized with either the live,
inactivated or inactivated and adjuvanted CORAVAX vaccines
developed high VNA titers against RABV. Similar to the antibodies
detected against SARS-CoV-2, the RABV VNA levels induced by
single vaccination with the live CORAVAX vaccine were the lowest
(about 6.7 IU), and the prime-boost immunization with the
adjuvanted CORAVAX vaccine induced the highest level (averaging 140 IU). Of note, all three approaches resulted in RABV VNA
levels way above the WHO protective titer of 0.5 IU.
Published in partnership with the Sealy Center for Vaccine Development

DISCUSSION
The results presented in this preclinical study indicate that
CORAVAX is an excellent candidate vaccine against COVID-19.
While several SARS-CoV-2 vaccine candidates are at an advanced
clinical phase, concerns for their efﬁciency remain. There have
been concerns that the urgent need for a COVID-19 vaccine has
pushed several vaccines into human trials without sufﬁcient
immunogenicity and a potential increase in antibody-mediated
pathology studies. The most advanced mRNA vaccine has no
animal data or clinical evaluation published, and information is
dependent on company press releases. The DNA vaccine platform
from two groups tested their vaccine responses in mice, guinea
pigs, and NHPs and provoked immunogenicity but low VNA
titers26,27. Another lead candidate, the adenovirus type 5 (Ad5)
vector expressing SARS-CoV S, has shown to be immunogenic but
induced low VNA titers in humans28. In another study, the SARSCoV-2 challenged animals continued to have some residual viral
RNA in the nasal swabs of ChAdOx1 nCoV-19 vaccinated NHPs,
raising the concern of vaccinated humans still being infectious29.
Another factor to consider is the longevity of the induced immune
responses. Adenovirus based vector previously analyzed as an
EBOV vaccine failed to induce long-term immunity, and the
protective responses against EBOV wore off three months after
immunization, requiring a boost with an unrelated vaccine
vector30.
The utilization of the S1 domain, rather than the full-length S,
might avoid concerns of binding of S2-speciﬁc non-neutralizing
antibodies enhancing inﬂammation and potentially causing
severe pathology. Certain antibody–virus immune complexes
could bind to activating Fc receptors on alveolar macrophages,
inducing the expression of pro-inﬂammatory factors, including IL6 and CCL2. The antibody–virus immune complexes could also
activate the complement system, which could further exacerbate
inﬂammation1. Previous research suggests that more than 90% of
humans already have antibodies against the four human
coronaviruses (HCoVs, e.g., 229E, OC43, NL63, HKU1)31. The several
highly conserved regions between the S2 domain of the four
human coronaviruses with that of SARS-CoV-2 are potential
targets for cross-reactive antibodies32. Therefore, immunization
with the SARS-CoV-2 S protein might enhance these conserved
epitopes and prevent a response against new epitopes in the S1
domain. Although not observed for coronaviruses, it has been
demonstrated that pre-existing immunity in ﬂavivirusesexperienced people can signiﬁcantly shape their B-cell response
against future ﬂavivirus infections33.
Besides the immunogenicity of a vaccine, there are two
concerns for the use of COVID-19 vaccines in humans: antibodydependent enhancement (ADE), as seen previously for RSV34, and
the vaccine-associated enhanced respiratory disease (VAERD).
While there is little evidence of ADE for coronaviruses, probably
because macrophages are not the primary target of human
coronaviruses, there are concerns of VAERD. Vaccine-induced Sspeciﬁc immunity induced after vaccination with a modiﬁed
vaccinia virus Ankara (MVA) resulted in severe acute lung injury
(ALI) in SARS-CoV challenged Chinese macaques compared to
vector MVA controls24. Such adverse effects need to be addressed
in animal systems before the mass vaccination of humans should
be pursued.
The success rate of the development of vaccines based on viral
vectored vaccines have been low, with the exception of the live
VSV based EBOV vaccine35. The signiﬁcant advantage of CORAVAX
is that it is an inactivated vaccine based on the rabies vector that
has been safely and effectively administered to pregnant women,
children, elderly, and the immunocompromised along with
inducing durable responses (CDC, MMWR). Also, the inactivated
rabies vectored EBOV vaccine, FiloRab1 has provided 100%
protection against EBOV challenge in NHP studies25. In summary,
npj Vaccines (2020) 98
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we have presented a novel vaccine against COVID-19 that is highly
immunogenic in an animal model. The detected VNA titers
induced by CORAVAX were much higher than the VNA detected in
human convalescent sera36. While this ﬁrst proof of concept study
utilized a high dose of live virus (107 ffu), studies with lower doses
of live virus and different amount of the killed vaccine will be
analyzed later. Of note, recent studies with adenoviruses or DNA
vaccines used viral titers up to 1011 pfu and amount of up to 100
micrograms RNA.
Further characterization of the immune response by different
vaccine doses and schedules to achieve protection, analyze
potential toxicity are currently performed, and the vaccine is
now manufactured. The ﬁrst clinical studies are expected to begin
in October 2020.
METHODS
Cells and viruses
BSR, Vero E6 cells, and Vero (CCL-81) were obtained from ATCC and were
cultured in 1X DMEM (Corning, Cat# 10-013-CV), supplemented with 5%
(v/v) fetal bovine serum (FBS), 1% (v/v) penicillin/streptomycin, and were
maintained at 37 °C and 5% CO2.
SARS-CoV-2 was obtained from BEI (WA-1 strain). Stocks were prepared
by infection of Vero E6 cells in 2% serum for ﬁve days, freeze-thawed, and
clariﬁed by centrifugation (PO). The titer of stock was determined by
plaque assay using Vero E6 cells and were 1 × 107 pfu/mL and 1.5 × 106
TCID50/mL. This seed stock was ampliﬁed in Vero CCL81 (P1) at 1.5 × 106
TCID50/mL. All work with infectious virus was performed in a Biosafety
Level 3 laboratory and approved by the Institutional Biosafety Committee
and Environmental Health and Safety.

Antibodies
SARS-COV/COV-2 S1 rabbit polyclonal sera obtained from Invitrogen, Cat#
PA5-81798. SARS-CoV-2 S1 mouse polyclonal sera were obtained from
mice immunized with a VSV vector expressing SARS-CoV2 S1. 4C12 AntiRABV-G human monoclonal was produced from 4C12 hybridoma
(provided by Dr. Scott Dessain, Lankenau Institute for Medical Research,
Wynnewood, PA).

Plasmid construction
The vaccine vector BNSP333 has been described previously37. Codonoptimized cDNA encoding SARS-CoV-2 Spike protein and RABV glycoprotein were obtained from Genscript. PCR fragments encoding amino acids
1-682 of SARS-CoV-2 and amino acids 428–524 of the SAD-B19 RABV
glycoprotein were ampliﬁed using primers CP1674P 5′-AAACTAAC
ACCCCTCCGTACGCCACCATGTTCGTGTTTCTGG-3′ and CP1675M 5′-CTCC
CACAGACCTTGGGGAGTTTGTCTGGG-3′ and primers CP1676P 5′-CTCCC
CAAGGTCTGTGGGAGATGAGGCCG-3′ and CP1677M 5′-TTAGTTTTTTTCA
TGGCTAGCTCACAGCCTGGTCTCGCC-3′, respectively. The two fragments
were joined and inserted between the BsiWI and NheI sites of BNSP333
using In-Fusion cloning (Takara Bio Inc., Mountain View, CA) to create
BNSP333-S1-RVG (CORAVAX). Recombinant clones were veriﬁed by DNA
sequencing.
Codons 16–681 of the spike protein gene were ampliﬁed using codonoptimized cDNA as template and primers CP1699P: 5′-TGACGCACCTA
GATCTGTGAACCTGACCACAAGGACC-3′ and CP1700M: 5′-CGTATGGA
TAGTCGACCCTTGGGGAGTTTGTCTGGG-3′ and inserted between the BglII
and SalI sites of the pDISPLAY vector to generate the expression plasmid
for production of soluble S1 fused to a C-terminal HA tag (Invitrogen Inc.,
Waltham, MA).

092) and polyclonal antiserum against the S1 domain (Thermo Fisher, Cat#
PA581798). The ﬁltered virus was then used to inoculate VERO cells seeded
in Cellstack Culture Chambers (Corning) and propagated in VP-SFM
medium (Thermo Fisher Scientiﬁc) over a period of 18 days. Supernatant
collected on day 10 post infection was ﬁltered through 0.45 µm PES
membrane ﬁlters (Nalgene) and layered onto 20% sucrose in DPBS. Virions
were sedimented by ultracentrifugation in a SW32 rotor for 1.5 h at
25,000 rpm. Viral particles were resuspended in phosphate-buffered saline
(PBS) and inactivated with 50 μl per mg of particles of a 1:100 dilution of
β-propiolactone (BPL, Millipore Sigma, Cat# P5648) in cold water. The
absence of infectious particles was veriﬁed by inoculating BSR cells with
10 μg of BPL-inactivated viruses over 3 passages.
For titration, a rabbit polyclonal antibody directed against the S1 subunit
of SARS Coronavirus (ThermoFisher, Cat# PA581798) was used for staining
overnight. The next day the cells were washed with DPBS and incubated
with a mixture of AlexaFluor 555 conjugated anti-rabbit-IgG (ThermoFisher,
Cat# A32794) and Dylight 488 conjugated monoclonal antibody 4C12 (Dr.
Scott Dessain) directed against the RABV glycoprotein. After overnight
staining, the cells were washed with DPBS, and ﬂuorescent foci counted to
determine viral titers.

Characterization of sucrose puriﬁed virions
Puriﬁed virus particles were denatured in 4× Laemmli Buffer (BIO-RAD,
Cat# 161-0747) supplemented with 10% beta-mercaptoethanol (w/v) at
95 °C for 5 min. Then 2.5 μg of total protein were resolved on a 10% SDSpolyacrylamide gel and thereafter stained overnight with Sypro Ruby for
total protein analysis or transferred onto a nitrocellulose membrane in
Towbin buffer (192 mM glycine, 25 mm Tris, 20% methanol) for western
blot analysis. The nitrocellulose membrane was then blocked in PBST (1X
PBS, 0.05% Tween-20) containing 5% (w/v) non-fat dried milk at room
temperature for 1 h. After blocking, the membrane was incubated
overnight with a human monoclonal 4C12 speciﬁc for the RABV
glycoprotein (hybridoma kindly provided by Dr. Scott Dessain) or rabbit
serum against the S1 subunit of SARS-CoV-2 Spike protein (Invitrogen,
ThermoFisher Scientiﬁc, Cat# PA5-81798) at a dilution of 1:1000 in PBS
containing 5% BSA. After washing, the western blot was incubated for 1 h
with anti-human IgG HRP (for RABV-G) at 1:20,000 or anti-rabbit-IgG HRP
(for SARS-CoV-2 S1) diluted 1:10,000 in blocking buffer. Bands were
developed with SuperSignal West Dura Chemiluminescent substrate
(Pierce, ThermoFisher Scientiﬁc Cat# 34075). Images were captured using
a FLuorChem R CCD imaging system (ProteinSimple). Color Prestained
Protein Standard, Broad Range (NEB #P7719) was used for molecular
weight determination. All gels or blots were derived from the same
experiment and were processed in parallel.

Immunoﬂuorescence
Vero E6 cells were seeded on coverslips in 1× DMEM (5% FBS) and infected
the following day with CORAVAX™ or control RABV (BNSP333) in 1X DMEM
(2% FBS) at 34 °C for 48 h. At the end of the incubation, the cells were
washed with 1X PBS, ﬁxed in 2% PFA for 30 min, and blocked with PBS
containing 5% FBS. The cells were then stained for 2 h at RT with mouse
polyclonal antiserum against the S1 subunit of SARS-CoV-2 Spike protein
and a human monoclonal antibody 4C12 against RABV glycoprotein (2 µg/
ml). Following washing with PBS and incubation with Cy3-conjugated antirabbit IgG HRP (1:200 in PBS containing 5% FBS, Jackson ImmunoResearch,
West Grove, PA, Cat# 711-035-152) and Cy2 conjugated anti-human IgG
HRP (1:250 in PBS containing 5% FBS, Jackson ImmunoResearch, Cat# 109225-088) secondary antibodies. The cells were mounted in ProLong™ Glass
Antifade Mountant with NucBlue™ Stain (Invitrogen, Cat# P36983). Images
were taken using Nikon A1R+ confocal microscope. Composite images
were prepared using Fuji.

Conformational characterization of chimeric S1 in CORAVAX
Virus puriﬁcation, inactivation and titration
Recombinant RABV were recovered, puriﬁed, inactivated and titered.
Brieﬂy, X-tremeGENE 9 transfection reagent (Millipore Sigma, Cat#
6365809001) was used to cotransfect the full-length viral cDNA clone
encoding CORAVAX along with the plasmids encoding RABV N, P, and L
proteins and the T7 RNA polymerase into BEAS-2B human lung cells in 6well plates (RABV). Eight days post transfection supernatant was collected,
ﬁltered through a 0.22 µm membrane ﬁlter (Millipore) and titrated on VERO
cells. The presence of recombinant virus was veriﬁed by immunostaining
with monoclonal antibody against the nucleoprotein (FujiRebio, Cat# 800npj Vaccines (2020) 98

Puriﬁed inactivated CORAVAX or control vaccine were coated in 3-fold
decreasing concentrations starting at 25 μg/mL. Control antigen RBD-His
was coated in 3-fold decreasing concentrations, starting at 300 ng/well A
constant amount of SARS COV/2 Anti-receptor binding domain (RBD)
mouse IgG2a antibody (InvivoGen, Cat # srbd-mab10, 1 μg/mL) or the
recombinant human ACE-2 Fc chimera (human IgG, Biolegend, Cat #
793208, 1 μg/mL) were added to the wells in 1% Milk in 1× PBST (0.05%
Tween-20). Secondary antibodies, goat anti-mouse IgG-Fc HRP (Southern
Biotech, Cat# 1033-05, 1:2000 in PBST) or goat Anti human IgG-Fc HRP
(Jackson ImmunoResearch, Cat# 109-035-098, 1:2000 in PBST) were used to
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detect the bound RBD mouse IgG2a antibody and human ACE-2 Fc
chimera (human IgG) protein respectively.
Optical density was measured at 490 nm and 630 nm using an ELX800
plate reader (Biotek Instruments, Inc., Winooski, VT). Background subtracted data (OD430 - 630 nm) were analyzed with GraphPad Prism
(Version 6.0 g) using 4-parameter nonlinear regression.

Animal ethics statement
This study was carried out in strict adherence to recommendations
described in the Guide for the Care and Use of Laboratory Animals, the
Ofﬁce of Animal Welfare, and the United States Department of Agriculture.
All animal work was approved by the Institutional Animal Care and Use
Committee (IACUC) at Thomas Jefferson University. All procedures were
carried out under isoﬂurane anesthesia by trained personnel and under the
supervision of veterinary staff. Mice were housed in cages in groups of ﬁve,
under controlled humidity, temperature, and light (12 h light/12 h dark
cycles) conditions. Food and water were available ad libidum.

Immunizations
Six- to -eight-week-old female BALB/c mice were purchased from Charles
River Laboratories (Wilmington, MA). Two groups of ﬁve mice were
inoculated intramuscularly with 10 µg of chemically inactivated CORAVAX™
particles, with and without adjuvant (5 µg MPLAs in 2.5% AddaVax,
Invitrogen, vac-mpls and vac-adx-10, respectively) in 100 µl PBS and
boosted once with the same amount of virus ± adjuvant on day 21,
respectively. Another group of ﬁve mice was immunized once with 108 ffu
of live CORAVAX™. Blood samples were collected by retro-orbital bleed
before the ﬁrst immunization until day 56 post-immunization.

Recombinant proteins for ELISA
Puriﬁcation of the HA-tagged protein from the supernatant of transfected
cells for ELISA. Sub-conﬂuent T175 ﬂasks of 293T cells (human embryonic
kidney cell line) were transfected with a pDisplay vector encoding amino
acids 16 to 682 of SARS-CoV-2 S (S1) fused to a C-terminal hemagglutinin
(HA) peptide using X-tremeGENE 9 reagent (Millipore Sigma, Cat#
6365809001). Supernatant was collected 6 days post-transfection, ﬁltered
through 0.22 um PES membrane ﬁlters (Nalgene) and the loaded onto an
anti-HA agarose (Pierce, Cat# 26182) column equilibrated in PBS. After
washing with ten bed volumes of PBS the column was loaded with 2
column volumes of HA peptide at a concentration of 400 µg/ml in PBS and
incubated overnight at 4 °C. The following day protein was eluted with 2
column volumes of HA peptide followed by two column volumes of PBS.
Fractions were collected and analyzed by western blotting with polyclonal
antiserum against the S1 domain (Thermo Fisher, Cat# PA581798). Peak
fractions were then pooled and dialyzed against PBS in 10,000 molecular
weight cutoff (MWCO) dialysis cassettes (Thermo Fisher Scientiﬁc) to
remove excess HA peptide. After dialysis, the protein was quantitated by
UV spectrophotometry and frozen in small aliquots at −80 °C.
Puriﬁcation of the RBD-His protein for ELISA. RBD-HIS38: The SARS COV-2
RBD-His tagged plasmid was purchased from Bei Resources (NR-52309).
Sub-conﬂuent T175 ﬂasks of 293T cells (human embryonic kidney cell line)
were transfected with the RBD-His tagged plasmid using X-tremeGENE 9
reagent (Millipore Sigma, Cat# 6365809001). Supernatant was collected
6 days post-transfection, ﬁltered through 0.22 μm PES membrane ﬁlters
(Nalgene). The 5 mL HisTALON cartridge (Clontech Laboratories, Cat #
635683) column was equilibrated with ten column volumes of Equilibration Buffer (HisTALON™ Buffer Set, Clontech Laboratories, Cat# 635651).
The ﬁltered supernatant was loaded onto the HisTALON cartridge
(Clontech Laboratories, Cat# 635683) column at a speed of 1 mL/min.
After washing with ten column volumes of Wash Buffer (Wash Buffer
prepared by mixing 6.6 parts of Elution Buffer with 93.4 parts of
Equilibration Buffer of the HisTALON™ Buffer Set), the sample is eluted
(at a ﬂow rate of ~1 ml/min) with approximately eight column volumes of
Elution Buffer, collecting 1 ml fractions. The sample protein concentration
was assessed by measuring the absorbance of the eluted fractions at
280 nm (Nanodrop, Thermo Fisher Scientiﬁc). Eluted fractions were
analyzed by Western blotting with a mouse monoclonal RBD speciﬁc
antibody (InvivoGen, Cat# srbd-mab10). Peak fractions were then pooled
and dialyzed against PBS in 10,000 molecular weight cutoff (MWCO)
dialysis cassettes (Thermo Fisher Scientiﬁc). After dialysis, the protein was
quantitated by UV spectrophotometry and frozen in small aliquots at
−80 °C.
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ELISA. To determine antibody responses to the S protein of SARS-CoV-2,
an indirect ELISA was developed utilizing puriﬁed S1 or receptor binding
domain (RBD) protein. The production of the recombinant proteins is
described above. Humoral responses to SARS-CoV-2 S1 and RBD protein
were measured by an indirect ELISA. We tested individual mouse sera by
enzyme-linked immunosorbent assay (ELISA) for the presence of IgG
speciﬁc to SARS-Cov-2 S1 or RBD. In order to test for anti-SARS COV-2 S1
humoral responses, we produced soluble S1 or RBD as described above.
The two recombinant proteins were resuspended in coating buffer (50 mM
Na2CO3 [pH 9.6]) at a concentration of 0.5 μg/mL of S1 or 2 μg/mL of RBD
and then plated in 96-well ELISA MaxiSorp plates (Nunc) at 100 μl in each
well. After overnight incubation at 4 °C, plates were washed three times
with 1× PBST (0.05% Tween 20 in 1× PBS), which was followed by the
addition of 250 μl blocking buffer (5% dry milk powder in 1× PBST) and
incubation at room temperature for 1.5 h. The plates were then washed
three times with PBST and incubated overnight at 4 °C with serial dilutions
of sera (in triplicate) in 1× PBST containing 0.5% BSA. Plates were washed
three times the next day, followed by the addition of goat anti-mouse-IgGFc HRP antibody (Southern Biotech, Cat# 1033-05, 1:8000 in PBST) or goat
anti-mouse-IgG1-Fc HRP antibody (Jackson ImmunoResearch, Cat# 115035-205, 1:8000 in PBST) or goat anti-mouse-IgG2a-Fc HRP antibody
(Jackson ImmunoResearch, Cat# 115-035-206, 1:8000 in PBST) for 2 h at RT.
After the incubation, plates were washed three times with PBST, and 200 μl
of o-phenylenediamine dihydrochloride (OPD) substrate (Sigma) was
added to each well. The reaction was stopped by the addition of 50 μl
of 3 M H2SO4 per well. Optical density was determined at 490 nm (OD490)
and 630 nm (OD630) using an ELX800 plate reader (Biotek Instruments, Inc.,
Winooski, VT). Plates were incubated for 15 mins (IgG-Fc) or 10 mins (IgG2a
or IgG1) with OPD substrate before the reaction was stopped with 3 M
H2SO4. Data were analyzed with GraphPad Prism (Version 8.0 g) using 4parameter nonlinear regression to determine the titer at which the curves
reach 50% of the top plateau value (50% effective concentration [EC50]).

SARS-COV-2 neutralization assays
Neutralizing virus titers were measured in serum samples that had been
heat-inactivated at 56 °C for 30 min. Duplicates of each serum dilution
were prepared in 96-well round-bottom plates starting at 1:50 dilution for
mouse sera and 1:5 dilution for human sera in a total volume of 40 µl
Optimem (1% Penicillin-Streptomycin). Vero CCL81 cells were plated in 96well plates (100 µL/well) at a density of 25,000 cells per well. The following
day, 100 pfu of SARS-CoV-2 was diluted into 30 µl DMEM and added to
each dilution of serum samples. The serum and virus were incubated
together at room temperature for 1 h and transferred to the supernatant of
the Vero CCL81 cells. Cells were incubated under standard cell culture
conditions at 37 °C and 5% CO2 for 48 h. Cells were ﬁxed in 4%
formaldehyde/PBS for 15 min at room temperature and then washed
three times with PBST. Cells were blocked (2% BSA/PBST) for 60 min and
incubated in primary antibody (anti-dsRNA J2) overnight at 4 °C. Cells were
washed 3× PBS and incubated in secondary (Goat anti-mouse Alexa 488ThermoFisher, Cat# A32723, and hoescht 33342-ThermoFisher, Cat#
H3570) for 2 h at room temperature. Cells were washed 3× in PBST and
imaged using ImagXpress Micro using a 10× objective. Four sites per well
were captured, and wells were scored for viral infection. The assay was
repeated twice (N = 2).

RABV neutralization by rapid ﬂuorescent-focus inhibition test
RABV virus neutralization was performed on BSR cells using CVS-11 strain
with triplicates of each sample by standard methods. In brief: Serum was
heat inactivated at 56 °C for 30 min. BSR cells (25,000 cells per well) were
preseeded in a 96 well ﬂat bottom plate 24 h prior to the assay. Serum
samples were threefold serially diluted in triplicates in a 96-well round
bottom plate, starting at a dilution of 1:30 for the mouse serum and 1:5 for
the human serum. The U.S. standard rabies immune globulin was used at a
starting dilution of 2 IU/mL. Working dilution of RABV CVS-11 strain (to get
90% infection) was prepared in 1X Optimem and 10 μL of the working
dilution was added to each well containing the diluted serum. Plates were
incubated for 1 h at 34 °C. Medium was aspirated from the 96-well plate
preseeded with BSR cells and the diluted serum+ virus mix was transferred
to the cells. Plates were incubated for 24 h at 34 °C. After the 24 h
incubation, plates were ﬁxed with 80% Acetone and stained with FITCconjugated anti-RABV N antibody. 50% endpoint titers were calculated
using the Reed -Muench method and converted to international unit (IU)
per milliliter by comparing to the U.S. standard Rabies immune globulin.
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Statistical analysis
For the ELISA, log transformed 50% effective concentration (EC50) titers
were plotting against delta OD value (OD 490–630 nm). One-way ANOVA
with post-hoc Tukey HSD test was performed on log transformed data for
each time point.

Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.

DATA AVAILABILITY
All data needed to evaluate the conclusions in the paper are present in the paper.
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